TB-500 + Epitalon Stack: Complete Protocol, Dosing, and Evidence Review

What Are TB-500 and Epitalon, and Why Are They Stacked?

TB-500 is a 7-amino-acid synthetic peptide (Ac-LKKTETQ) corresponding to the actin-binding domain of thymosin beta-4, a 43-amino-acid protein that appears in nearly every nucleated mammalian cell. Thymosin beta-4 regulates actin polymerization, which governs cell migration, wound closure, and angiogenesis. A 2010 paper in the Annals of the New York Academy of Sciences identified the Ac-LKKTETQ fragment as the primary bioactive region responsible for the parent protein's tissue-repair effects 1.

Epitalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly) synthesized to replicate the activity of epithalamin, a polypeptide extract from bovine pineal glands. Its primary proposed mechanism is activation of telomerase, the enzyme that adds TTAGGG repeats to chromosomal telomere ends, potentially slowing telomere shortening that accompanies cellular aging 2.

The two peptides are stacked because their proposed actions operate on different timescales and different biological targets. TB-500 addresses short-term tissue-repair signaling; Epitalon addresses longer-range cellular aging processes. Practitioners report combining them during recovery phases to address both acute injury and underlying cellular biology at the same time.

The Actin-Regulation Mechanism of TB-500

Thymosin beta-4 sequesters G-actin monomers, controlling the pool available for filamentous actin assembly. The Ac-LKKTETQ fragment retains this binding activity. In a murine full-thickness dermal wound model, topical thymosin beta-4 accelerated wound closure by 41.6% compared with vehicle control at day 7 (P<0.01) 3. Subcutaneous systemic delivery produced comparable directional effects, which is the basis for injectable use in practitioner protocols.

Epitalon's Telomerase-Activation Evidence

A 2002 study published in Neuroendocrinology Letters by Khavinson and colleagues examined Epitalon in human somatic cells in vitro and reported telomerase activity increases, with the treated cell cultures displaying statistically longer mean telomere length after multiple passages compared with untreated controls 2. The same research group reported that epithalamin administration in elderly patients over a 3-year period was associated with a 1.6- to 1.8-fold reduction in mortality compared with historical control groups, though that study lacked blinding and randomization 4.

Why Stack These Two Peptides?

The rationale is mechanistic complementarity rather than proven combination. TB-500 targets the acute inflammatory and repair cascade via actin dynamics and upregulation of anti-inflammatory cytokines. Epitalon targets the pituitary-pineal axis, melatonin regulation, and telomere maintenance. Neither mechanism directly interferes with the other at the receptor or enzymatic level, which is the primary argument practitioners use to justify combined use. No pharmacokinetic data confirm the absence of interaction.

Current Evidence Base: What the Research Actually Shows

The honest summary: animal and in-vitro data exist for each peptide separately; no peer-reviewed human RCT has studied either peptide in isolation for the indications practitioners typically use them for, and zero published studies have examined the combination.

TB-500 Preclinical Data

In a rat myocardial infarction model published in Nature, systemic thymosin beta-4 given after coronary ligation improved fractional shortening by 10.8 percentage points versus saline at 28 days and promoted cardiomyocyte survival in the border zone 5. A separate equine tendon repair study found that horses receiving intra-lesional thymosin beta-4 showed more organized collagen fiber alignment at 8 weeks histologically, though sample sizes were small (n=12 per group) 6.

No FDA-approved clinical indication exists for TB-500 in humans. The FDA has not granted it Investigational New Drug status for musculoskeletal repair, and the agency explicitly classifies peptides sold outside a licensed compounding pharmacy as unapproved drugs 7.

Epitalon Human Evidence

The most cited human data come from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. A prospective cohort study (N=266 elderly subjects, mean age 75 years) compared epithalamin or Epitalon administration over 3 years to a non-randomized control group. The treated group showed a 28% lower incidence of cardiovascular complications and a statistically significant improvement in melatonin secretion amplitude 4. The absence of randomization and blinding in that study limits causal inference considerably.

A separate in-vitro investigation demonstrated that Epitalon at a concentration of 0.01 nM increased telomerase activity in human fetal fibroblasts by approximately 33% over passage-matched untreated cultures 2. Whether that translates to meaningful telomere preservation in a living human over a multi-year timeframe has not been tested in a blinded trial.

What the Evidence Gap Means Clinically

Both peptides sit in a zone sometimes called "promising preclinical, inconclusive human." Practitioners and patients who use these peptides are doing so outside any regulatory-approved indication. Informed consent should include an explicit acknowledgment of that gap.

Dosing and Protocol Design for the TB-500 + Epitalon Stack

Because no published pharmacokinetic study has examined the two peptides together, the protocol below is synthesized from the separate dosing literature for each peptide and practitioner-reported schedules. A HealthRX clinician should review this framework before any patient applies it.

TB-500 Dosing Phase

The most commonly reported TB-500 loading protocol uses 4 to 10 mg subcutaneously twice per week for 4 to 6 weeks. The lower end of that range (4 to 5 mg) is typically recommended for general recovery and anti-inflammatory goals; the higher end (7 to 10 mg) appears in protocols targeting significant musculoskeletal injury. After loading, a maintenance dose of 2 to 2.5 mg once or twice per month is frequently described in practitioner communities.

Injection sites reported in the literature and clinical case reports include subcutaneous abdominal fat, lateral thigh, and deltoid. Intramuscular injection into a site near an injury has also been described, though direct evidence that local injection outperforms systemic subcutaneous injection is limited.

Reconstitution follows standard lyophilized peptide procedure: bacteriostatic water is added to the vial, gently swirled (not shaken), and stored refrigerated at 2 to 8°C after reconstitution. Stability data in published literature support approximately 28-day post-reconstitution refrigerated storage, though formal pharmaceutical stability studies specific to TB-500 are not available in the public domain.

Epitalon Dosing Phase

Epitalon dosing in Khavinson's published cohorts used 10 mg per day administered intramuscularly for 10 consecutive days, repeated two to three times per year 4. Subcutaneous injection has become more common in modern practitioner protocols because it is less uncomfortable and produces comparable tissue exposure based on general peptide pharmacokinetic principles. Daily doses of 5 to 10 mg for 10 to 20 days per cycle are the most frequently described range outside clinical research settings.

Some practitioners prefer a nasal spray formulation at 1 to 2 mg per nostril twice daily, though mucosal absorption data for Epitalon specifically are not published in peer-reviewed literature.

Combining the Two Peptides: Sequencing Options

Two timing strategies appear in practitioner literature.

Parallel dosing: TB-500 and Epitalon are run simultaneously, with TB-500 given on its twice-weekly schedule and Epitalon given daily (or on Khavinson's 10-consecutive-day cycle) during the same calendar period. This is the more common approach when the goal is recovery from a specific injury paired with general longevity support.

Sequential dosing: A 4-to-6-week TB-500 loading phase runs first, followed immediately by a 10-to-20-day Epitalon cycle. Some practitioners favor this because it simplifies the injection schedule and allows clearer attribution of any adverse response.

No comparative data exist to favor one approach over the other. Patient preference, injection burden tolerance, and cost typically determine the choice.

Cycle Length and Frequency

A typical annual TB-500 + Epitalon cycle structure reported by practitioners looks like this:

| Period | TB-500 | Epitalon | |---|---|---| | Weeks 1 to 6 | 4 to 10 mg twice weekly (loading) | 5 to 10 mg daily (or 10-day pulse) | | Weeks 7 to 24 | 2 to 2.5 mg once or twice monthly (maintenance) | Off | | Weeks 25 to 28 | Off | 5 to 10 mg daily repeat cycle | | Weeks 29 to 52 | 2 to 2.5 mg monthly as needed | Off or third short cycle |

This framework is not derived from a single published protocol. It represents a synthesis of the Khavinson cohort dosing, preclinical TB-500 dosing extrapolated to human body surface area equivalents, and practitioner-reported schedules.

Safety Profile and Adverse Effects

TB-500 Adverse Effects

Reported adverse effects in the preclinical literature are limited. In the rat cardiac studies, no organ toxicity signals emerged at doses up to 150 mcg/kg 5. Human adverse event data come from case reports and informal practitioner surveys rather than systematic pharmacovigilance. The most commonly reported human adverse effects include transient fatigue and mild headache in the first few days of loading, and local injection-site reactions. A theoretical concern about TB-500 promoting angiogenesis in the context of an occult tumor exists because thymosin beta-4 upregulates vascular endothelial growth factor signaling 8. This concern has not been confirmed in human observational data, but it supports screening for active malignancy before use.

Epitalon Adverse Effects

Khavinson's cohorts reported no serious adverse events attributable to Epitalon administration over 3-year follow-up periods 4. Transient injection-site erythema and mild drowsiness the evening following administration are the most commonly described effects. The pineal-axis and melatonin-augmenting activity of Epitalon means it may alter sleep architecture; patients with sleep disorders should use it cautiously and preferably dose in the evening.

Contraindications

Based on the current evidence base, practitioners generally avoid or delay both peptides in the following situations:

• Active malignancy or recent cancer history (VEGF concern with TB-500)
• Pregnancy or breastfeeding (no safety data)
• Active autoimmune disease treated with immunosuppressants (thymosin beta-4 modulates immune cell migration) 9
• Age <18 years (no pediatric data)

Drug Interactions

No published pharmacokinetic drug-interaction studies exist for either peptide. Theoretical interactions include additive melatonin effects when Epitalon is combined with exogenous melatonin or melatonin agonists such as ramelteon, and possible additive anti-inflammatory effects when TB-500 is combined with NSAIDs or corticosteroids, which could theoretically impair the same inflammatory cascades that drive tissue remodeling.

Regulatory Status and Sourcing Considerations

Neither TB-500 nor Epitalon holds FDA approval for any human indication. The FDA's compounding guidance makes clear that peptides not on the 503A or 503B bulks lists cannot be legally compounded for patient use by licensed pharmacies in the United States 7. Both peptides are sold openly by research chemical vendors as "research use only" products. Quality, purity, and accurate labeling of those products are not guaranteed by any regulatory body.

Independent laboratory analysis of peptides purchased from research chemical suppliers has found significant variance in purity. A 2022 analysis referenced in practitioner networks found purity values ranging from 62% to 99% across ten vendors for a similarly unregulated peptide, highlighting the sourcing risk. Patients should request a certificate of analysis (CoA) with mass spectrometry confirmation before using any peptide from an unregulated source.

Anti-doping considerations are real. The World Anti-Doping Agency (WADA) prohibits thymosin beta-4 and all its fragments, including TB-500, under Section S2 of the Prohibited List (peptide hormones, growth factors, related substances) 10. Competitive athletes subject to testing should not use TB-500 regardless of the clinical rationale.

Monitoring and Lab Work

Practitioners who oversee patients using the TB-500 + Epitalon stack typically recommend baseline and follow-up labs to establish safety and track relevant biomarkers.

Baseline Labs

A reasonable baseline panel before starting the stack includes:

• Complete blood count with differential (to establish immune baseline; thymosin beta-4 influences T-cell and macrophage activity)
• Comprehensive metabolic panel (hepatic and renal function)
• C-reactive protein and erythrocyte sedimentation rate (inflammatory markers)
• Insulin-like growth factor 1 (IGF-1, because growth factor peptides as a class have been associated with IGF-1 axis changes in some models) 8
• Serum melatonin (morning trough), if available, to assess pineal axis baseline before Epitalon

Follow-Up Assessment

A 6-to-8-week follow-up panel after the TB-500 loading phase and the first Epitalon cycle gives a practical picture of any emergent signals. Telomere length testing (via quantitative PCR or flow-FISH from a specialized laboratory) is sometimes ordered by longevity-focused practitioners before and 6 months after an Epitalon cycle, though the clinical significance of small inter-test telomere length changes in an individual is not established 11.

Who Is a Candidate for This Stack?

The TB-500 + Epitalon combination is most often discussed in three patient profiles:

1. Musculoskeletal recovery with longevity interest. An adult over 40 recovering from tendon or ligament injury who also wants to address biological aging markers may find the combined protocol appealing because it targets both goals in the same 6-to-8-week window.

2. Post-injury or post-surgical acceleration. Some practitioners use TB-500 specifically in the 4-to-8-week window after soft tissue surgery, where the animal data on wound closure and collagen organization are most relevant 3, and add Epitalon to support the neuroendocrine environment during recovery.

3. Longevity-focused adults without acute injury. People using Epitalon primarily for its telomerase-activation and circadian effects may add a short TB-500 pulse for its reported anti-inflammatory and angiogenic support, reasoning that both contribute to healthspan.

None of these use cases has been validated in a controlled human trial. Any prescribing or recommending clinician should document the off-label, investigational nature of the protocol in the patient's chart.